Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy

Berger, William; Abelson, Mark B.; Gomes, Paulo; Beck, Morris; Kimura, Stephen; Westbrook, Thomas; Storms, William W.; Galant, Stanley P.

doi:10.1016/s1081-1206(10)61155-6

Cited by 44 publications

(29 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SAC and PAC can often go undiagnosed, or the ocular component of allergic rhinoconjunctivitis can go untreated. The signs and symptoms of allergic conjunctivitis have a meaningful effect on patients' quality of life, 4 health, and comfort. Brief diagnostic questioning, examination, and prescription of appropriate topical ocular therapy or addition of this therapy to an existing medication regimen are the keys to appropriate management of ocular allergy and maintenance of patient health and satisfaction.…”

Section: Vkc and Akcmentioning

confidence: 99%

See 1 more Smart Citation

Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment

Ono¹,

Abelson²

2005

Journal of Allergy and Clinical Immunology

Self Cite

285

199

View full text Add to dashboard Cite

Section: Vkc and Akcmentioning

confidence: 99%

“…In one study (n = 200) approximately 90% of patients with rhinitis indicated they had experienced at least 1 day of ocular symptoms within the past week. 4 Patient-reported signs and symptoms are critical to the diagnosis of allergic conjunctivitis because signs and symptoms might not be present at the time of the visit.…”

mentioning

confidence: 99%

Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment

Ono¹,

Abelson²

2005

Journal of Allergy and Clinical Immunology

Self Cite

285

199

View full text Add to dashboard Cite

“…Berger et al conducted a prospective multicenter crossover study that involved 200 patients with allergic rhinitis. Of these, 90.5% had some concurrent ocular symptoms, and ocular treatment with olopatadine hydrochloride 0.1% eye drops combined with nasal treatment improved ocular allergic symptoms and their QOL compared with the nasal treatment only (Berger et al 2005). From the results in CAC studies, it may be possible that olopatadine hydrochloride 0.1% or 0.2% ophthalmic solution has an important role if used for these multi-organ cases by resolving ocular symptoms promptly and potently.…”

Section: Possibility Of Future Optional Use Of Olopatadine Eye Dropsmentioning

confidence: 99%

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops

Uchio¹

2008

OPTH

View full text Add to dashboard Cite

Olopatadine hydrochloride exerts a wide range of pharmacological actions such as histamine H1 receptor antagonist action, chemical mediator suppressive action, and eosinophil infiltration suppressive action. Olopatadine hydrochloride 0.1% ophthalmic solution (Patanol®) was introduced to the market in Japan in October 2006. In a conjunctival allergen challenge (CAC) test, olopatadine hydrochloride 0.1% ophthalmic solution significantly suppressed ocular itching and hyperemia compared with levocabastine hydrochloride 0.05% ophthalmic solution, and the number of patients who complained of ocular discomfort was lower in the olopatadine group than in the levocabastine group. Conjunctival cell membrane disruption was observed in vitro in the ketotifen fumarate group, epinastine hydrochloride group, and azelastine hydrochloride group, but not in the olopatadine hydrochloride 0.1% ophthalmic solution group, which may potentially explain the lower discomfort felt by patients on instillation. Many other studies in humans have revealed the superiority of olopatadine 0.1% hydrochloride eye drops to several other anti-allergic eye drops. Overseas, olopatadine hydrochloride 0.2% ophthalmic solution for a once-daily regimen has been marketed under the brand name of Pataday®. It is expected that olopatadine hydrochloride ophthalmic solutions may be used in patients with a more severe spectrum of allergic conjunctival diseases, such as vernal keratoconjunctivitis or atopic keratoconjunctivitis, in the near future.

show abstract

“…In one recent study, 90.5% of patients with allergy symptoms who were using systemic or nasal therapies also had ocular symptoms. Adding olopatadine as an adjuvant to these patients' medication regimens relieved their ocular symptoms and significantly improved their overall quality of life [33]. Olopatadine is currently the only agent approved by the US Food and Drug Administration (FDA) for comprehensive treatment of all signs and symptoms of allergic conjunctivitis.…”

Section: Multiple-action Agents Olopatadinementioning

confidence: 99%

Ocular allergy in pediatric practice

Abelson

Granet²

2006

Curr Allergy Asthma Rep

Self Cite

View full text Add to dashboard Cite

Allergies occur frequently in all pediatric age groups, affecting up to 40% of children. Allergic conjunctivitis is the most common ocular allergy syndrome among children, with atopic keratoconjunctivitis and vernal keratoconjunctivitis comprising less common, but potentially more severe, forms of ocular allergy. In this article, we review the impact, diagnosis, potential complications, and treatment of these ocular allergic pediatric conditions. Early detection is necessary to prevent potentially serious consequences of pediatric ocular allergy. Involvement of pediatric ophthalmologists may be necessary to avoid preventable vision loss in severe cases.

show abstract

Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy

Cited by 44 publications

References 20 publications

Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment

Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops

Ocular allergy in pediatric practice

Contact Info

Product

Resources

About